Low-dose corticosteroids during severe community-acquired pneumonia: End of the story

European Respiratory Journal

Volumn 45, Issue 2, 2015, Pages 305-307

  Ricard, Jean Damien ^a   Messika, Jonathan ^b  

^a HÔPITAL LOUIS MOURIER   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOLAMINE; CORTICOSTEROID; HYDROCORTISONE; PLACEBO; PREDNISOLONE;

ACUTE RESPIRATORY FAILURE; ADULT RESPIRATORY DISTRESS SYNDROME; ANTIBIOTIC RESISTANCE; ARTIFICIAL VENTILATION; BACTERIAL VIRULENCE; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; CORTICOSTEROID THERAPY; DISEASE MODEL; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG SAFETY; ESCHERICHIA COLI PNEUMONIA; HUMAN; INFECTION RISK; INTENSIVE CARE UNIT; LOW DRUG DOSE; MORTALITY; MUSCLE WEAKNESS; NONHUMAN; PSEUDOMONAS PNEUMONIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEPSIS; SEPTIC SHOCK; SUPERINFECTION; TREATMENT DURATION; TREATMENT OUTCOME; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; MALE; PNEUMONIA;

ADRENAL CORTEX HORMONES; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HUMANS; MALE; PNEUMONIA;

EID: 84922128449     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00225414     Document Type: Review

References (23)

1. Menendez R, Torres A, Reyes S, et al. Initial management of pneumonia and sepsis: factors associated with improved outcome. Eur Respir J 2012;39:156-162.
2. Waterer GW, Rello J, Wunderink RG. Management of community-acquired pneumonia in adults. Am J Respir Crit Care Med 2011;183:157-164.
3. Gattarello S, Borgatta B, Sole-Violan J, et al. Decrease in mortality in severe community-acquired pneumococcal pneumonia: impact of improving antibiotic strategies (2000-2013). Chest 2014;146:22-31.
4. Cheng DS, Han W, Chen SM, et al. Airway epithelium controls lung inflammation and injury through the NF-κB pathway. J Immunol 2007;178:6504-6513.
5. Mizgerd JP, Lupa MM, Hjoberg J, et al. Roles for early response cytokines during Escherichia coli pneumonia revealed by mice with combined deficiencies of all signaling receptors for TNF and IL-1. Am J Physiol 2004;286:L1302-L1310.
6. Mizgerd JP, Spieker MR, Doerschuk CM. Early response cytokines and innate immunity: essential roles for TNF receptor 1 and type I IL-1 receptor during Escherichia coli pneumonia in mice. J Immunol 2001;166:4042-4048.
7. Gibot S, Alauzet C, Massin F, et al. Modulation of the triggering receptor expressed on myeloid cells-1 pathway during pneumonia in rats. J Infect Dis 2006;194:975-983.
8. Allen KS, Kinasewitz GT. The pendulum of corticosteroids in sepsis swings again? Crit Care Med 2014;42:2442-2443.
9. Funk D, Doucette S, Pisipati A, et al. Low-dose corticosteroid treatment in septic shock: a propensity-matching study. Crit Care Med 2014;42:2333-2341.
10. Tagami T, Matsui H, Horiguchi H, et al. Low-dose corticosteroid use and mortality in severe community-acquired pneumonia patients. Eur Respir J 2014;45:463-472.
11. Borah BJ, Moriarty JP, Crown WH, et al. Applications of propensity score methods in observational comparative effectiveness and safety research: where have we come and where should we go? J Comp Eff Res 2014;3:63-78.
12. Confalonieri M, Urbino R, Potena A, et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med 2005;171:242-248.
13. Meijvis SC, Hardeman H, Remmelts HH, et al. Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. Lancet 2011;377:2023-2030.
14. Snijders D, Daniels JM, de Graaff CS, et al. Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial. Am J Respir Crit Care Med 2010;181:975-982.
15. Nie W, Zhang Y, Cheng J, et al. Corticosteroids in the treatment of community-acquired pneumonia in adults: a meta-analysis. PLoS One 2012;7:e47926.
16. Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008;358:111-124.
17. De Jonghe B, Sharshar T, Lefaucheur JP, et al. Paresis acquired in the intensive care unit: a prospective multicenter study. JAMA 2002;288:2859-2867.
18. De Jonghe B, Lacherade JC, Sharshar T, et al. Intensive care unit-acquired weakness: risk factors and prevention. Crit Care Med 2009;37:Suppl., S309-S315.
19. Brun-Buisson C, Richard JC, Mercat A, et al. Early corticosteroids in severe influenza A/H1N1 pneumonia and acute respiratory distress syndrome. Am J Respir Crit Care Med 2011;183:1200-1206.
20. Martin-Loeches I, Lisboa T, Rhodes A, et al. Use of early corticosteroid therapy on ICU admission in patients affected by severe pandemic (H1N1) v influenza A infection. Intensive Care Med 2011;37:272-283.
21. Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam JS, et al. Effect of corticosteroid therapy on influenza-related mortality: a systematic review and metaanalysis. J Infect Dis 2014 [In press DOI: 10.1093/infdis/jiu645].
22. Messika J, Sztrymf B, Bertrand F, et al. Risks of nonsteroidal antiinflammatory drugs in undiagnosed intensive care unit pneumococcal pneumonia: younger and more severely affected patients. J Crit Care 2014;29:733-738.
23. Voiriot G, Dury S, Parrot A, et al. Nonsteroidal antiinflammatory drugs may affect the presentation and course of community-acquired pneumonia. Chest 2011;139:387-394.